Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

More spinout companies are created by the University of Oxford than any other UK University and an increasing number of their founders and senior leaders are women.

Female headshot with business icons

One such company is Omass Therapeutics which spun out of the Department for Chemistry in 2016. It utilises high-resolution mass spectrometry to drive drug discovery for immunology and genetic disease and last year received $100million investment to advance its technology. The company has two female founders, a female CEO and a female Vice President. The company also has a gender balanced board. 

Nucleome Therapeutics is another female-led company which spun out of the University in 2019. This fast-emerging biopharma uses cutting-edge 3D genome technologies and machine learning to find genetic drivers of disease, and design drugs against them. Last year, the company raised £37.5 million to continue to decode the genetics hidden in the ‘dark’ regions of the human genome and advance its autoimmune disease programmes.

Dr Danuta Jeziorska, founder and CEO of Nucleome Therapeutics, said: ‘I am thrilled to see more women pursuing careers in the biotech industry. During my time at Oxford, I leveraged support from various entrepreneurial initiatives, Saïd Business School, and directed the Innovation Forum and Oxfordshire Women in Tech network. Having access to the right guidance and mentorship is crucial to fostering a diverse business community where women are empowered with the confidence to realise the fullest extent of their ambitions.’

Yet recent research from the Centre for Diversity Policy Research and Practice at Oxford Brookes University shows that only 18% of spinout companies have a woman founder and this is reflective of the global picture of women across business and industry where fewer than a quarter hold senior leadership positions.

Through its IDEA programme, the University of Oxford is committed to tackling some of the key challenges and inequalities faced by groups who are currently vastly underrepresented in enterprise and industry across the world. Its first initiatives are aimed at empowering, inspiring, connecting and upskilling more women leaders, business founders and pioneers.

Read the full story on the University of Oxford website

Similar stories

RECOVERY trial team awarded MRC Impact Prize for Outstanding Team Impact

The Medical Research Council Prize Committee has awarded the RECOVERY trial team the MRC Impact Prize 2022 for Outstanding Team Impact.

Professor Sir Chris Whitty brings greater understanding of epidemics to Oxford

Chief Medical Officer of England Professor Sir Chris Whitty KCB FMedSci delivers the Sherrington Prize Lecture: Public Understanding of Science to an audience of Oxford staff and students.

Multiple Debilitating Pains – New global study shows the experience of Endometriosis is rooted in a person’s genetics

Researchers at the University of Oxford in collaboration with 25 teams across the world have published the largest study to date of the genetic basis of endometriosis.

Study shows delaying treatment for localised prostate cancer does not increase mortality risk

Active monitoring of prostate cancer has the same high survival rates after 15 years as radiotherapy or surgery, reports the largest study of its kind.

Showcasing Oxford’s translational research for Rare Disease Day

Rare Disease Day is an annual awareness day that aims to educate and raise awareness for the 400 million people worldwide who live with a rare disease.

Prostate cancer AI diagnosis tool begins evaluation in Oxford

New artificial intelligence software that can help to spot prostate cancer is being trialled by researchers at Oxford University Hospitals (OUH) NHS Foundation Trust.